Policy Considerations for Developing TCM Predominant Diseases Under DRG/DIP Payment

China Health Insurance ›› 2023, Vol. 0 ›› Issue (7) : 23-29.

China Health Insurance ›› 2023, Vol. 0 ›› Issue (7) : 23-29. DOI: 10.19546/j.issn.1674-3830.2023.7.003
Observation & Discussion

Policy Considerations for Developing TCM Predominant Diseases Under DRG/DIP Payment

Author information +
History +

Abstract

Exploring the scope, standards, and methods of traditional Chinese medicine (TCM) payment by disease, supporting and promoting the inheritance, innovation, and development of TCM within the framework of DRG/DIP policy is an important task in establishing a collaborative promotion mechanism for payment method reform. This article discusses and analyzes the necessity of carrying out medical insurance payment for TCM predominant diseases under the background of DRG/DIP payment method reform, as well as the concept and selection criteria of TCM predominant diseases. Corresponding suggestions are proposed to provide a reference for the development of medical insurance payment for TCM predominant diseases.

Key words

TCM predominant diseases / medical insurance payment / DRG / DIP

Cite this article

Download Citations
Policy Considerations for Developing TCM Predominant Diseases Under DRG/DIP Payment[J]. China Health Insurance. 2023, 0(7): 23-29 https://doi.org/10.19546/j.issn.1674-3830.2023.7.003

References

[1] 国务院办公厅.关于印发“十四五”全民医疗保障规划的通知:国办发〔2021〕36号[A/OL].(2021-09-29)[2023-05-12].https://www.gov.cn/zhengce/content/2021-09/29/content_5639967.htm.
[2] 国家医疗保障局.关于印发DRG/DIP支付方式改革三年行动计划的通知:医保发〔2021〕48号[A/OL].(2021-11-26)[2023-05-12].http://www.nhsa.gov.cn/art/2021/11/26/art_104_7413.html.
[3] 国家医疗保障局,国家中医药管理局.关于医保支持中医药传承创新发展的指导意见:医保函〔2021〕229号[A/OL].(2021-12-31)[2023-05-12].http://www.nhsa.gov.cn/art/2021/12/31/art_104_7721.html.
[4] 烟建华.中医优势病种专家调查及其理论探源[J].江苏中医,2001,22(9):1-4.
[5] 刘应科,孙光荣.中医优势病种的认识及发展建议[J].湖南中医药大学学报,2022,42(3):498-503.
[6] 季聪华,郭清.基于循证医学的中医优势病种评价标准思考[J].中华中医药杂志,2022,37(1):277-280.
[7] 林奕,王学谦,赵晖,等.中医优势病种评价的方法学探讨[J].中医杂志,2021,62(19):1663-1667.
[8] 黄亚博,冯广清.中医优势病种调查方法学研究及其应用评价[J].江苏中医药,2012,44(12):1-3.
[9] 孙立明.关于中医优势病种研究的评述和建议[J].中华中医药杂志,2022,37(3):1271-1273.
[10] 杨思红,赵晖,梁宁,等.中医优势病种遴选和评价技术指导建议[J].中国中医基础医学杂志,2022,28(10):1595-1601.
[11] 杨海丰,崔志伟,王茂,等.我国中医优势病种分布状况及特点[J].中医杂志,2012,53(4):285-287.
[12] 黄亚博,冯广清.江苏省中医中西医结合内科优势病种调查研究[J].江苏中医药,2013,45(9):5-8.
[13] 陈容焕,管红叶.上海首批22个中医优势病种试点按疗效价值付费[J].中医药管理杂志,2022,30(16):205.
[14] 广东省医疗保障局.关于开展医保支付改革促进中医药传承创新发展的指导意见:粤医保发〔2021〕43号[A/OL].(2021-09-30)[2023-05-12].http://hsa.gd.gov.cn/gkmlpt/content/3/3678/post_3678593.html#3835.
[15] 汕尾市医疗保障局.关于印发汕尾市中医优势病种与中医日间病房医保支付方式改革实施办法的通知:汕医保〔2022〕61号[A/OL].(2022-08-9)[2023-05-12].https://www.shanwei.gov.cn/swybj/zwgk/0200/0201/content/post_843682.html.
[16] 刁仁昌,薛虹,吴尚勇.江苏南京中医DRG的分组逻辑与改革成效[J],中国卫生,2022,8:61-64.
[17] 陈菊,曹继忠,黄玲,等.中医优势病种医疗质量管理系统[J].成都中医药大学学报,2017,40(2):5-8.

Accesses

Citation

Detail

Sections
Recommended

/